These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Cardiac response to early conversion from calcineurin inhibitor to everolimus in renal transplant recipients--a three-yr serial echocardiographic substudy of the randomized controlled CENTRAL trial. Murbraech K; Massey R; Undset LH; Midtvedt K; Holdaas H; Aakhus S Clin Transplant; 2015 Aug; 29(8):678-84. PubMed ID: 25982053 [TBL] [Abstract][Full Text] [Related]
25. Pharmacoepidemiology of anemia in kidney transplant recipients. Winkelmayer WC; Kewalramani R; Rutstein M; Gabardi S; Vonvisger T; Chandraker A J Am Soc Nephrol; 2004 May; 15(5):1347-52. PubMed ID: 15100376 [TBL] [Abstract][Full Text] [Related]
26. Everolimus represents an advance in immunosuppression for patients who have developed cancer after renal transplantation. González E; Andrés A; Polanco N; Hernández A; Morales E; Hernandez E; Huerta A; Ortuño T; Gutiérrez Martínez E; Praga M; Morales JM Transplant Proc; 2009; 41(6):2332-3. PubMed ID: 19715911 [TBL] [Abstract][Full Text] [Related]
27. Cyclosporine lowering with everolimus versus mycophenolate mofetil in heart transplant recipients: long-term follow-up of the SHIRAKISS randomized, prospective study. Potena L; Prestinenzi P; Bianchi IG; Masetti M; Romani P; Magnani G; Fallani F; Coccolo F; Russo A; Ponticelli C; Rapezzi C; Grigioni F; Branzi A J Heart Lung Transplant; 2012 Jun; 31(6):565-70. PubMed ID: 22341702 [TBL] [Abstract][Full Text] [Related]
28. Level of renal function and serum erythropoietin levels independently predict anaemia post-renal transplantation. Sinnamon KT; Courtney AE; Maxwell AP; McNamee PT; Savage G; Fogarty DG Nephrol Dial Transplant; 2007 Jul; 22(7):1969-73. PubMed ID: 17353209 [TBL] [Abstract][Full Text] [Related]
29. Wound events in kidney transplant patients receiving de novo everolimus: a pooled analysis of three randomized controlled trials. Cooper M; Wiseman AC; Zibari G; McCague K; Kim Y; Geissler F; Nashan B Clin Transplant; 2013; 27(6):E625-35. PubMed ID: 24033455 [TBL] [Abstract][Full Text] [Related]
30. Thyroid status and kidney transplantation outcomes. Papalia T; Greco R; Lofaro D; Mollica A; Bonofiglio R Transplant Proc; 2011 May; 43(4):1042-4. PubMed ID: 21620048 [TBL] [Abstract][Full Text] [Related]
31. De novo everolimus-based therapy in renal transplant recipients: effect on proteinuria and renal prognosis. Loriga G; Ciccarese M; Pala PG; Satta RP; Fanelli V; Manca ML; Serra G; Dessole P; Cossu M Transplant Proc; 2010 May; 42(4):1297-302. PubMed ID: 20534285 [TBL] [Abstract][Full Text] [Related]
32. Observational study with everolimus (Certican) in combination with low-dose cyclosporine in de novo heart transplant recipients. Lehmkuhl HB; Mai D; Dandel M; Knosalla C; Hiemann NE; Grauhan O; Huebler M; Pasic M; Weng Y; Meyer R; Rothenburger M; Hummel M; Hetzer R J Heart Lung Transplant; 2007 Jul; 26(7):700-4. PubMed ID: 17613400 [TBL] [Abstract][Full Text] [Related]
33. [Incidence and management of anemia in renal transplantation: an observational-French study]. Choukroun G; Deray G; Glotz D; Lebranchu Y; Dussol B; Bourbigot B; Lefrançois N; Cassuto-Viguier E; Toupance O; Hacen C; Lang P; Mazouz H; Martinez F Nephrol Ther; 2008 Dec; 4(7):575-83. PubMed ID: 18672417 [TBL] [Abstract][Full Text] [Related]